SECURITIES AND EXCHANGE COMMISSION

                   Washington, D.C.  20549


                          FORM 10-Q


     QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE
               SECURITIES EXCHANGE ACT OF 1934

For Quarter Ended                  June 30, 2000

Commission file number             33-56574


                        DIASENSOR.COM
   (Exact name of registrant as specified in its charter)



Pennsylvania                                25-1605848
(State or other jurisdiction               (IRS Employer
of incorporation or organization)        Identification no.)


  2275 Swallow Hill Road, Bldg. 2500; Pittsburgh, PA 15220
(Address of principal executive offices)       ( Zip Code)

                       (412) 279-9740
     Registrant's telephone number, including area code

     Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by section 13 or
15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90
days.
                                   Yes   X        No

     As of June 30, 2000, 22,980,051 shares of
Diasensor.com, Inc. common stock, par value $.01 were
outstanding.

<PAGE>1

                               DIASENSOR.COM, INC.
                         (A Development Stage Company)
                          Consolidated Balance Sheets

                                         June 30,     September 30,
 ASSETS                                    2000           1999
                                        (Unaudited)
                                        -----------    -----------
Current assets
  Cash and cash equivalents (note A)    $    13,324    $    6,525
  Prepaid expenses                             -              130
                                        -----------    -----------
               Total current assets          13,324         6,655

Property and equipment - at cost (note A)
  Furniture and fixtures                     42,750        42,750
  Less accumulated depreciation              32,911        28,331
                                        -----------    -----------
                                              9,839        14,419
                                        -----------    -----------


Other assets
  Due from BICO (note A)                      -         1,458,809
  Allowance for doubtful account              -        (1,458,809)
  Investment - MicroIslet, Inc. (note E)    454,167          -
  Investment - Diabecore (note E)           500,784          -
  Security Deposit                           17,500        17,250
                                        -----------    -----------
                                            972,451        17,250
                                        -----------    -----------
 TOTAL ASSETS                       $       995,614    $   38,324
                                        ===========    ===========

               LIABILITIES and STOCKHOLDERS' EQUITY

Current liabilities
  Accounts payable                      $     -        $     -
  Due to BICO                               884,275          -
  Accrued payroll and withholdings           91,840        91,214
                                        -----------    -----------
           Total current liabilities        976,115        91,214


Commitments and Contingencies (notes A and D)

Stockholders' equity (deficiency)
  Preferred stock, 1,000,000 shares authorized, none issued
  Common stock, 40,000,000 shares of $.01 par value
   authorized; issued and outstanding 22,980,051 at
   Jun. 30, 2000 and 22,980,051 at
   Sep. 30, 1999                            229,801       229,801
  Additional paid-in capital             26,892,071    26,892,071
  Warrants                               18,684,017    18,453,839
  Deficit accumulated during the
  development stage                     (45,786,390)  (45,628,601)
                                        -----------    -----------
                                             19,499       (52,890)
               TOTAL LIABILITIES AND    -----------    -----------
                  STOCKHOLDERS' EQUITY  $   995,614   $    38,324
                                        ===========    ===========
[FN]
The accompanying notes are an integral part of this statement.

<PAGE>2
                             DIASENSOR.COM, INC.
                     (A Development Stage Company)

<TABLE>
                  Consolidated Statement of Operations
                              (Unaudited)
<CAPTION>
                                          For the nine months ended     For the three months ended   From July 5, 1989
                                                  June 30,                      June 30,            (inception) through
                                             2000             1999         2000            1999        June 30, 2000
                                          -------------------------    --------------------------  -------------------
</CAPTION>
<S>                                      <C>              <C>              <C>              <C>            <C>
Research and development expenses       $       -       $     -       $     -        $      -     $      10,556,405

General and administrative expenses        1,603,807        628,438      682,959         349,613         14,875,938

Provision for (recovery of) doubtful      (1,458,809)      (488,016)        -           (451,680)             -
accounts

Warrant extensions                              -             -             -               -            18,184,986

Technology and patent rights acquired         12,791         49,857        3,332             620          2,662,791

Interest expense                                -             1,499         -               -                10,529

Other income                                    -           (37,394)        -            (10,988)          (571,664)

Other expense                                   -             -             -               -                37,405
					  -------------------------    --------------------------  -------------------
         Net loss                       $   (157,789)   $  (154,384)  $ (686,291)    $   112,435  $     (45,756,390)
                                          ===========    ===========   ===========    ===========   ===================
Net income (loss) per common share      $      (0.01)   $     (0.01)  $    (0.03)    $      0.00  $           (2.40)
                                          ===========    ===========   ===========    ===========   ===================

See notes to the financial statements.
</TABLE>
<PAGE>3
<TABLE>
                            DIASENSOR.COM, INC.
                     (A Development Stage Company)

                        Statement of Cash Flows
                              (Unaudited)


<CAPTION>

                                                For the nine months ended  For the three months ended  From July 5,1989
                                                          June 30,                    June 30,         (Inception) thru
                                                    2000            1999         2000          1999       June 30, 2000
                                                 ------------------------   -------------------------- ----------------
 <S>                                             <C>             <C>            <C>           <C>           <C>
Cash flows from operating activities
 Net Income (Loss)                          $    (157,789)      $ (154,384)   $  (686,291)  $   112,435  $ (45,756,390)
 Adjustments to reconcile net loss to net
  cash used by operating activites:
   Depreciation                                     4,580          (42,749)         1,527         1,527         80,207
   Amortization of goodwill                        45,833            -             25,000          -            45,833
   Provision for (recovery of) doubtful        (1,458,809)        (505,916)          -         (469,580)          -
   accounts
   Impairment loss                                    -              -               -             -            14,367
   Stock in exchange for services                     -              -               -             -           138,950
   Stock issued for License and Marketing Agreement   -              -               -             -            80,000
   Warrants issued for services                   230,178            -            229,074          -           458,716
   Warrent extensions                                 -              -               -             -        18,184,986
   Inventory deposit-BICO                             -              -               -             -        (1,000,000)
   (Increase) Decrease in prepaid expenses            130          (14,771)         2,638        18,350           -
   Increase in payable due to BICO                921,669            -            449,134          -        11,421,669
   Increase (Decrease) in accounts payable            -            (23,606)       (12,500)      (11,107)          -
   Increase in accrued payroll and withholdings       626           24,176              1       (12,136)        91,840
   (Increase) in other assets                        (250)           -               -             -           (17,500)
                                                 ------------    -----------  ------------  -------------  ------------
   Net cash used in operating activities         (413,832)        (717,250)         8,583      (360,511)   (16,257,322)

Cash flows from investing activities:
 Disposal of property and equipment                   -            222,296         -             -             175,000
 Purchase of property and equipment                   -              -             -             -            (279,413)
 Investment - MicroIslet, Inc.                   (500,000)           -             -             -            (500,000)
 Investment - Diabecore                          (500,784)           -             -             -            (500,784)
 Increase in Notes Receivable			      -              -             -             -            (125,000)
 Increase in Interest Receivable                      -             (5,142)        -             -             (13,538)
                                               -------------  -------------  ------------ ------------   -------------
   Net cash (used) in investing activities     (1,000,784)         217,154         -             -          (1,243,735)

Cash flows from financing activities:
 Advances to BICO                                (437,405)        (377,727)        -           (203,290)    (7,498,369)
 Repayment of advances to BICO                  1,858,820          938,011         -            656,123      9,166,099
 Proceeds from issuance of common stock               -              -             -             -          10,971,834
 Proceeds from issuance of common stock to BICO       -              -             -             -           4,200,000
 Proceeds from warrants exercised                     -              -             -             -             118,066
 Proceeds from treasury stock                         -              -             -             -             (35,000)
 Proceeds from Regulation S                           -              -             -             -             288,751
 Proceeds from issuance of notes payable              -              -             -             -             303,000
                                               -------------- -------------- ------------- -------------  -------------
Net cash provided by financing activities       1,421,415          560,284         -            452,833     17,514,381
                                               -------------- -------------- ------------- -------------  -------------
Net increase (decrease) in cash and cash equiv.     6,799           60,188          8,583        92,322         13,324
Cash and cash equivalents at beginning of period    6,525           41,811          4,741         9,677           -
                                               -------------- -------------- ------------- -------------  -------------
Cash and cash equivalents at end of period  $      13,324     $    101,999    $    13,324   $   101,999  $      13,324
                                               ============== ============== ============= ============  ==============

See notes to the financial statements.
</TABLE>

                     DIASENSOR.COM, INC.

         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


NOTE A - Basis of Presentation

     The accompanying financial statements of Diasensor.com,
Inc.  (the "Company") have been prepared in accordance  with
generally   accepted  accounting  principles   for   interim
financial information, and with the instructions to Form 10-
Q  and  Rule 10-O Regulation S-X.  Accordingly, they do  not
include  all  of the information and footnotes  required  by
generally   accepted  accounting  principles  for   complete
financial  statements.  In the opinion  of  management,  all
adjustments   (consisting  of  normal  recurring   accruals)
considered  necessary  for  a fair  presentation  have  been
included.   For further information, refer to the  financial
statements  and  footnotes included in the Company's  annual
report on Form 10-K for the fiscal year ended September  30,
1999.

NOTE B - Organization

     The  Company  was incorporated on July 5,  1989  as  a
wholly owned subsidiary of BICO, Inc.  BICO owns 52% of  the
stock of the Company as of June 30, 2000.  Diasensor.com  is
currently  developing a noninvasive glucose sensor (Sensor).
The  sensor would use electromagnetic technology to  measure
blood without requiring the user to take a blood sample.

NOTE C - Net Loss Per Common Share

     Net  loss  per common share is based on  the  weighted
average  number of outstanding common shares, which amounted
to  22,980,051 and 22,980,051 for the periods ended June 30,
2000  and  June 30, 1999, respectively. The loss  per  share
does  not include common stock equivalents since the  effect
would be anti-dilutive.

     From July 5, 1989 (inception) to June 30, 2000, net loss
per  common share is based on the weighted average number  of
common  shares  outstanding and the number of  common  shares
issuable  on  the  exercise of 1,708,000 warrants  issued  in
1992;  reduced by 488,000 common shares that were assumed  to
have  been  purchased with the proceeds from the exercise  of
the  warrants  at an assumed price of $3.50 per  share.   The
inclusion  of the warrants in the loss per share  calculation
is  required  by  the  rules of the Securities  and  Exchange
Commission  relative  to the initial registration  statement,
which included the Company's financial statements through the
period  ended  March  31,  1993.  The registration  statement
became  effective July 19, 1993.  The weighted average number
of  common  shares including the effect of the conversion  of
the  warrants amounted to 19,551,945 for the period from July
5, 1989 (inception) to June 30, 2000.


                     DIASENSOR.COM, INC.

   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

NOTE D - Legal Proceedings

     In April, 1998, the Company and its affiliates were
served with subpoenas by the U.S. Attorneys' office; the
Company has produced documents in response to such
subpoenas.  The class action suit which names the Company as
a defendant remains in the pre-trial pleading stage pursuant
to consent of all the parties.

NOTE E - Investments in Unconsolidated Subsidiaries

     In January 2000, the Company acquired a ten percent
(10%) interest in MicroIslet, Inc. for an investment of
$500,000.  MicroIslet is a California company which has
licensed several diabetes research technologies from Duke
University with a specific focus on optimizing
microencapsulated islets for transplantation.

     In March 2000, the Company acquired an equity interest
in Diabecore Medical, Inc., a Toronto-based company working
to develop a new insulin for the treatment of diabetes, for
$500,784.  With this initial investment, the Company owns
12% of Diabecore, advancing to a 35% ownership at completion
of funding through July 2001.

     Both investments are being reported on the equity basis
and differences in the investment and the underlying net
assets of the unconsolidated subsidiaries is being amortized
as goodwill over a 5 year period.

Management's Discussion and Analysis of Financial Condition and Cash Flows


Liquidity and Capital Resources

     During the nine months ended June 30, 2000 funds  were
transferred  to  Diasensor from BICO to repay  advances  and
provide working capital.  These funds were used in operating
activities    and    for   investments   in   unconsolidated
subsidiaries.  The net effect of these cash transactions was
to  increase  cash  from $6,525 at September  30,  1999,  to
$13,324 at June 30, 2000.

     As  of  June  30, 2000, amounts due from BICO  to  the
company was zero, compared to $1,458,809 as of September 30,
1999.    The  decrease  was  due  to  repayment   of   funds
transferred  from  the  Company  to  BICO.   Due  to  BICO's
financial  condition, an allowance for doubtful accounts  in
the  same  amount as the funds due to the Company from  BICO
had  been established in the fiscal year ended September 30,
1999.  Because the full amount was repaid, the allowance for
doubtful accounts was also adjusted in the same amount  from
($1,458,809) to zero.

     The  Company's  investments  in  MicroIslet,  Inc.  and
Diabecore, Inc. occurred during the quarter ended March  31,
2000.   As  a  result, these other assets were $454,167  and
$500,784, respectively, as of June 30, 2000, as compared  to
zero at September 30, 1999.

     Amounts  due  to  BICO from the Company increased  from
zero as of September 30, 1999 to $884,275.  This increase is
due  to intercompany transfers from BICO to the Company  for
working capital.

Results of Operations

     There were no research and development expenses during
the  nine months period ended June 30, 2000 and 1999 due  to
the  agreed-upon suspension of billings by Diasensor.com and
BICO pursuant to the research and development agreement.

     General  and Administrative expenses increased  during
the  second quarter from $349,613 for the three month period
ended  June 30, 1999 to $682,959 for the three month  period
ended June 30, 2000 and increased from $628,438 for the nine
month period ended June 30, 1999 to $1,603,807 for the  nine
month  period  ended  June  30,  2000.   The  increase   was
primarily  due to an increase in salaries and administrative
staff, along with administrative overhead.

     The  Company recovered $1,458,809 in doubtful accounts
during  the  nine month period ended June 30, 2000.  All  of
these  recoveries were prior to March 31, 2000 and therefore
none  were  recognized in the three month period ended  June
30, 2000.  Similar recoveries of $488,016 were recognized in
the  nine month period ended June 30, 1999 of which $451,680
were  in the three months ended June 30, 1999. This recovery
was  due  to  BICO's  repayments of intercompany  transfers,
which  had  been fully reserved as doubtful  accounts  as  a
result of BICO's financial condition during the prior years.

     Because   of   the  fluctuations   in   General   and
Administrative  expenses and recovery of doubtful  accounts,
as  discussed  above, the Company's net loss was  ($157,789)
for  the nine months ended June 30, 2000 and ($686,291)  for
the  three months ended June 30, 2000, as compared to a  net
loss  of ($154,384) and net income of $112,435 for the prior
years' periods, respectively.


     Other  income during the third quarter decreased  from
$10,998 for the three month period ended June 30, 1999 to $0
for the three month period ended June 30, 2000 and decreased
from  $37,394 for the nine month period ended June 30,  1999
to  $0 for the nine month period ended June 30, 2000.   This
decrease  was  due to a reduction in rental income  and  the
Company  having  lower cash reserves to  invest  during  the
period  ending  June 30, 2000 than during the period  ending
June 30, 1999.
                PART II -- OTHER INFORMATION

Item 1.        Legal Proceedings
               None.

Item 2.        Changes in Securities
               None.

Item 3.        Defaults Upon Senior Securities
               None.

Item 4.        Submission of Matters to a Vote of Security Holders
               None.

Item 5.        Other Information
               None.

Item 6.        Reports on Form 8-K
               None.

SIGNATURES


     Pursuant to the requirements of the Securities Exchange
Act  of 1934, the registrant has duly caused this report  to
be  signed  on its behalf by the undersigned thereunto  duly
authorized on this 15th day of August, 2000.


                              DIASENSOR.COM, INC.

                              By /s/ Fred E. Cooper
                                     Fred E. Cooper
                                     President and Director (principal
                                     executive officer,principal financial
                                     officer and principal accounting
                                     officer)